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-   
Activation of innate immune responses to arbovirus at the mosquito bite prevents efficient 25 
systemic dissemination of virus.  
 
 
Arthropod-borne viruses (arboviruses) are important human pathogens for which there are no 
specific antiviral medicines. The abundance of genetically distinct arbovirus species, coupled 30 
with the unpredictable nature of their outbreaks, has made developing virus-specific 
treatments challenging. Instead, we have defined and targeted a key aspect of the host innate 
immune response to virus at the arthropod bite that is common to all arbovirus infections, 
potentially circumventing the need for virus-specific therapies. Using mouse models and 
human skin explants, we identify innate immune responses by dermal macrophages in the 35 
skin as a key determinant of disease severity. Post-exposure treatment of the inoculation site 
by a topical TLR7 agonist suppressed both the local and subsequent systemic course of 
infection with a variety of arboviruses from the Alphavirus, Flavivirus, and Orthobunyavirus 
genuses.  Clinical outcome was improved in mice following infection with a model Alphavirus. 
In the absence of treatment, anti-viral interferon expression to virus in the skin was restricted 40 
to dermal dendritic cells. In contrast, stimulating the more populous skin-resident 
macrophages with a TLR7 agonist elicited protective responses in key cellular targets of virus 
that otherwise proficiently replicated virus. By defining and targeting a key aspect of the 
innate immune response to virus at the mosquito bite site, we have identified a putative new 
strategy for limiting disease following infection with a variety of genetically-distinct 45 
arboviruses. 
n 
Emerging and re-emerging arboviruses pose an increasing threat to human health. There has 
been a substantial increase in both the incidence and geographical range of medically-
important arboviruses spread by mosquitoes, which infect hundreds of millions of people each 50 
year and include the Zika (ZIKV), dengue (DENV) and chikungunya (CHIKV) viruses. 
Arboviruses are a large, genetically-diverse group of viruses that cause a wide spectrum of 
diseases in humans (1Ð5). Despite their genetic diversity, it is nonetheless difficult to clinically 
differentiate between these infections in the early stages of disease, as they are either 
asymptomatic or present as a non-specific febrile viral illness. In many geographic areas this 55 
is compounded by the widespread co-circulation of distinct species of arboviruses in the same 
geographic area (6). Together, these factors complicate the use of putative virus-specific anti-
virals, which for acute infections are most often only efficacious when given during early stages 
(7). This, when combined with our inability to accurately predict the timing and location of 
future epidemics (8), makes stockpiling future virus-specific drugs and vaccines difficult. 60 
Currently, there are few vaccines and no antivirals available for arbovirus infections. We 
suggest that due to the diversity of arbovirus genetics, their common clinical features and 
their unpredictable epidemiology, the development of a pan-viral medicine that is efficacious 
for multiple arbovirus infections would be highly advantageous.  
Infected mosquitoes deposit virus into the skin dermis as they probe for a bloodmeal, 65 
triggering activation of distinct inflammatory pathways in response to mosquito biting and to 
virus sensing (9Ð11). We and others have demonstrated that host responses in the skin to 
mosquito biting, or mosquito saliva, has a defining influence on the systemic course of 
infection for a wide variety of genetically-distinct arboviruses including flaviviruses, 
alphaviruses and bunyaviruses (10Ð14). As such, this is a key stage of infection during which 70 
virus replicates rapidly before disseminating to the blood and remote tissues. Indeed, the 
majority of virus in the blood at 24 hours post infection of the skin is likely derived from 
replication at this site (9). However, some of the original virus inoculum also disseminates 
directly to the blood and the draining lymph node (dLN) where replication is also established 
prior to systemic dissemination (9, 13). Thus, it is not clear what role skin-specific innate 75 
immune responses, activated by virus sensing at the mosquito bite, has on modulating the 
subsequent systemic course. In this study, we wanted to define the relevance of skin virus-
sensing pathways and determine whether this can be targeted to modulate outcome of 
infection.  
Innate immune sensing of virus activates immune pathways that are distinct to those activated 80 
by mosquito biting, resulting in expression of type I interferons (IFN) and the anti-viral genes 
they upregulate, IFN-stimulated genes (ISG). Despite the evolution of multiple strategies by 
arboviruses to counteract IFN they are nonetheless highly sensitive to them, suggesting that 
therapies designed to target these pathways could be generalisable to a range of viruses (15Ð
18). Systemic administration of type I IFN has been used to treat hepatitis C virus, although 85 
febrile-like side effects are common (19) and as such it is not suitable for e.g. long-term 
prophylactic use. However, previous attempts to inhibit arbovirus infection by systemic 
administration of innate immune agonists or type I IFN have only been efficacious when given 
prior to infection (20Ð24). In contrast, we suggest targeting processes at the inoculation site, 
which represents a discreet identifiable locale that can be targeted post-mosquito bite, prior 90 
to the systemic dissemination of virus. However, targeting these pathways is challenging as 
the coordination of early innate immune responses to virus at mosquito bites are not well 
defined. 
Studying innate immune responses at the tissue- and system-wide level to arboviruses that 
are medically-important in humans, has been frequently complicated by their inability to 95 
replicate in immunocompetent mice (10). Therefore, we chose to primarily study host innate 
immune responses to a prototypic model arbovirus Semliki Forest virus (SFV; genus 
Alphavirus). Unlike most human arboviral pathogens, SFV is capable of efficiently replicating, 
disseminating systemically within, and causing clinically-observable disease in 
immunocompetent mice (25). SFV is a close relative of CHIKV that has a large number of 100 
genetically-modified clones and has been used extensively to study host response to infection 
(26). SFV replicates quickly following infection of mouse skin, with viremia peaking by 24 hours 
post-infection (hpi). Dissemination of SFV to brain tissue can result in encephalitis, 
neurological signs and death (9, 25). Clinical outcome of SFV infection in mice most likely 
reflects the efficiency by which virus seeds brain tissue.  105 
In this study, we define key aspects of host response to virus at mosquito bites and 
demonstrate that this can be therapeutically modulated to suppress viral replication and the 
development of clinical disease. We suggest that for virus to successfully disseminate from 
the skin to the blood at a sufficient level to induce a high-titre viremia, sufficiently robust 
replication must occur at the inoculation site prior to a host IFN induced anti-viral state. Using 110 
an immune-competent mouse model of arbovirus infection and ex vivo infection of human 
skin explants, we investigate therapeutic manipulation of skin IFN pathways by post-exposure 
topical application of a widely-used generic innate immune agonist for infection with multiple 
genetically-distinct arboviruses.  
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We wanted to determine whether targeting early innate immune responses in the skin had 
any observable effect on the later systemic course of infection. However, it was first necessary 120 
to define the kinetics and magnitude of endogenous host ISG responses to infection with 
SFV6 (a virulent strain of SFV), in the absence of therapies. Following infection of the foot skin, 
ISG expression in response to virus was slow and of low-magnitude, with ISG expression not 
significantly elevated until 24 hpi or later, peaking at 48 hpi (Fig 1A-D). In comparison, the dLN 
rapidly and robustly upregulated ISG, with amounts peaking by 16 hpi. Thus, upregulation of 125 
anti-viral ISG in the skin could be detected only after virus had disseminated systemically (9).  
It is not clear what relevance skin-specific innate immune responses to arbovirus have on the 
subsequent systemic course of infection, nor whether virus replication in the skin is absolutely 
necessary to establish viremia. To determine whether therapeutic induction of anti-viral innate 
immune pathways at the inoculation site could have any effect on the systemic course of 130 
infection, we injected or topically applied to a defined cutaneous site a range of innate 
immune agonists one hour prior to infection with SFV6 (Fig 1E-K). The TLR7 agonist imiquimod 
(IMQ) was administered either as a subcutaneous (s.c.) injection or applied topically as a cream 
(Aldara, topical IMQ). To assess success of virus infection viral RNA was measured by qPCR 
and infectious virus assayed by plaque assay. Virus RNA measured by qPCR represented sum 135 
total of genome and replicated viral transcripts. To define the contribution made by the 
original inoculum towards the level of viral RNA assayed by qPCR at 24hpi, mice were 
inoculated with the UV-inactivated virus (which can infect cells but does not replicate). Copy 
number of viral RNA were close to the detection limit of the assay at 24 hpi, suggesting non-
replicating virus was rapidly cleared in vivo (Fig S1A).  140 
At 24 hpi, only topical IMQ and poly(I:C)-treated mice exhibited lower viral RNA at the skin 
inoculation site, whereas all innate immune agonists decreased virus in the dLN (Fig 1E). 
Poly(I:C) was particularly potent at decreasing viral RNA in most tissues analyzed, although 
viremia (Fig 1G) and survival to infection (Fig 1K) was not significantly affected. In comparison, 
only topical IMQ significantly  decreased viral replication at both local tissues (skin and dLN, 145 
p<0.05), tissues remote from the inoculation site (non-dLN (p<0.01), spleen(p<0.01) and brain 
(p<0.05)), reduced infectious virus in blood (p<0.001), and limited the development of clinical 
disease (Fig 1H, p<0.05). As SFV6 is highly virulent in mice, it does not model all arboviral 
disease seen in humans that are often non-fatal. Therefore, to better model the human 
situation we also tested the ability of IMQ to suppress infection with SFV4, a less virulent strain 150 
than SFV6 (Fig S1B). Again, application of topical IMQ at the site of SFV4 inoculation 
significantly (p<0.01) suppressed infection.  
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Treatment modalities that target early stages of infection are likely to involve post-exposure 
treatment, e.g. once the erythema of a bite is apparent. Because pre-bite application of 
topical IMQ was most efficacious in increasing host resistance to infection, we next 
determined its efficacy when applied post-infection. In addition, as arbovirus infection of skin 
always occurs in the context of an arthropod bite, we used a mouse model that additionally 160 
incorporates biting Aedes aegypti mosquitoes. Host response to mosquito bites include 
edema and an influx of leukocytes that enhances host susceptibility to infection with virus (9, 
10, 27). Because topical IMQ is a cream that can become removed by cage bedding, it was 
first applied at 1 hpi and then re-applied once at 6 hpi to maintain dosing. In this model, 
application of topical IMQ was highly efficacious in lowering quantities of SFV6 RNA in all 165 
tissues analysed and infectious virus in the blood by 24 hpi (Fig 2A-B). For mice in which 
infection was allowed to progress, topical IMQ application resulted in a significant delay to 
the onset of neurological signs (Fig 2C, (p<0.0001). Consistent with this, analyses of brain 
tissue at post infection day 7 revealed extensive expression of SFV6-encoded mCherry 
throughout the brain in untreated mice compared to treated mice (Fig 2D). 170 
Similarly, topical IMQ at 1hpi post infection with the less virulent SFV4 strain significantly 
reduced virus by 24 hpi in tissues  and the blood (p<0.01) and substantially decreased 
mortality (p<0.001), with the majority of mice surviving infection (Fig 2E-G).  Importantly, 
protection by topical IMQ was time-limited, as treatment 5 hpi significantly lowered viral RNA 
(p<0.05 in skin and spleen), but treatment delayed until 10 hpi did not significantly modulate 175 
the level of viral replication or dissemination by 24 hpi (Fig 2H). 
Although these experiments were designed to test the ability of immune modulators to target 
the inoculation site, it is possible that mice inadvertently consumed some topical IMQ orally 
e.g. during grooming. In the above studies, mice were given topical IMQ at 1 hpi, during 
which the mice were anesthetised. Mice did not fully recover from anaesthesia until after 5 180 
hpi, during which the majority of topical IMQ would have been absorbed and was not 
available for oral consumption. Nonetheless, to define the contribution that inadvertent oral 
consumption of topical IMQ had on susceptibility to virus infection, we washed away 
unabsorbed topical IMQ from the inoculation site using a mild detergent aqueous wash 
immediately prior to recovery from anaesthesia. In addition, a separate group of mice 185 
received topical IMQ as an oral gavage (10% Aldara in water). Mice washed at 5 hpi still 
exhibited significantly (p<0.05) reduced amounts of virus at the skin inoculation site, spleen 
and the blood by 24hpi. In comparison, those mice given IMQ as an oral gavage exhibited no 
significant reduction of virus (Figure 2I).  Together this suggests that topical IMQ was primarily 
modulating the course of virus infection through responses activated at the site of application.  190 
The above studies involved virus infection of mouse skin by needle at sites of mosquito biting, 
because mosquito saliva has profound modulatory effects on host susceptibility to virus (10, 
11). Because infection of the mosquito salivary gland by virus can alter salivary protein content 
(28), it is possible that virus inoculated by infected mosquitoes themselves has additional 
effects on modulating virus infection in the mammalian host. To determine if topical IMQ is 195 
also efficacious in altering host susceptibility to virus in the presence of saliva from infected 
mosquitoes, we obtained saliva from SFV-infected mosquitoes and co-inoculated it with a 
SFV6 into mouse skin (Figure S1C). To ensure that we inoculated similar quantities of virus as 
in our other experiments, infected saliva was firstly irradiated with UV to inactivate salivary 
gland-derived virus, and then a defined dose of SFV6 added prior to inculcation into mice. By 200 
24hpi, those mice that received topical IMQ treatment exhibited significantly (p<0.01) less 
virus in the serum and spleen. Thus, irrespective of changes in virus-induced salivary gland 
gene expression, topical IMQ was effective at inhibiting virus infection in mice. Together these 
data identify the inoculation site as a key site for viral replication during the first 24 hpi and 
suggests that, in untreated mice, skin IFN responses are not sufficiently robust to prevent 205 
systemic dissemination. Therapeutic targeting of this site with topically applied innate 
immune agonists was therefore highly effective at suppressing both the local and subsequent 
systemic course of infection, significantly improving survival.  
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We next wanted to determine the mode of action, as a detailed mechanistic understanding 
of this protection could inform the development of more targeted strategies. Topical IMQ 
contains a mixture of the TLR7 agonist IMQ (5%) and isostearic acid (25%), both of which can 
be inflammatory in a type I IFN-independent manner (29, 30), suggesting that IFN may be 215 
dispensable for some of the beneficial effects described here. However, we found that by 24 
hours post application at a mosquito bite, topical IMQ caused widespread induction of ISG 
expression, including the prototypic ISGs cxcl10, ifit1, isg15 and rsad2 (Fig. 3A), some of which 
have been identified as key responders to alphavirus infection (17, 31). Cxcl10 could only be 
detected significantly upregulated by 24 hours (Fig. S2A, p<0.01). Interestingly however, 220 
despite a clear upregulation of ISG, we could not detect any increase in type I (ifna4, ifnb1, 
ifne, ifnk, ifnz) or II (ifng1) IFN transcripts in whole skin biopsies, as measured by Taqman assays 
or custom SYBR green qPCR assays (Fig. 3A, S2A,B), suggesting topical IMQ may activate ISG 
expression independent of IFN receptor signalling in the skin (32). Conceivably, our inability 
to detect type I IFN transcripts in wild type mice skin may be due to large numbers of IFN-225 
negative cells that diluted the IFN signal, or because IFN-producing cells migrated out of the 
skin, rendering IFN undetectable.  
Anti-viral ISG can be induced by a variety of distinct receptors, including signalling through 
IFN-ab-R, IFNGR, IFNLR1 and other poorly-defined non-canonical pathways (16, 32). However, 
we found that activation of skin ISG was dependent on IFN-ab-R signalling, as mice deficient 230 
in this receptor could not upregulate these prototypic ISGs in response to topical IMQ (Fig. 
3B). Importantly, loss of IFN signalling was associated with a loss of protection from infection, 
as topical IMQ had no impact on virus replication in IFN-ab-R null mice (Fig. 3C,D). In addition, 
to specifically show that the IMQ component was essential for protection against virus, we 
treated mouse skin with a cream mimic that lacked IMQ but contained 25% w/w isostearic 235 
acid (29), which did not protect mice from infection (Fig. 3E). Nonetheless, itÕs likely that these 
excipients are required for a maximal IFN response, as injection of IMQ alone had little or no 
effect on ISG expression (Fig. S2C-F), nor did it have any effect on virus replication, as shown 
above (Fig. 1E-G, and Fig. S1B). 
In comparison to skin responses, topical IMQ upregulated both IFN and ISG in the dLN; IFNg 240 
was significantly elevated by 8h post application (p<0.05, Fig S2G), while type I IFNs and ISGs 
were detectable by 24 hours (Fig. 3F, Fig. S2G). In agreement with previous studies in humans 
(33), there was a limited systemic response to topical IMQ, although our qPCR assay was 
sufficiently sensitive to detect some type I IFN expression in distal lymphoid tissue sites, but 
not e.g.  remote skin or joints (Fig. 3G). 245 
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We next wanted to identify the cellular basis by which virus is detected and an anti-viral state 
induced and modulated by topical IMQ at mosquito bites. Although a variety of cultured skin 250 
cells are known to express RNA-virus pattern recognition receptors (34), the cellular 
coordination of innate immune responses to arbovirus at the mosquito bite are not described. 
We concentrated on studying cells of the dermis, as the majority of virus transmitted by 
mosquito is deposited here, and because epidermal cells do not express the IMQ receptor 
TLR7 in vivo (35). To identify whether bite-recruited leukocytes or skin-resident cells are 255 
sufficient for detecting IMQ and eliciting protection from virus, we developed a skin model in 
which freshly biopsied mouse skin was taken from either resting skin or mosquito-bitten skin 
(4 h post bite, during leukocyte influx (9)) and infected with Gaussia-luciferase expressing SFV6 
(SFV6-Gluc), which enables longitudinal detection of virus at high sensitivity, in vitro. Mosquito 
biting results in the rapid recruitment of leukocytes including neutrophils and monocytes (9), 260 
and as shown here small numbers of pDCs (Fig 4A). Infection of skin explants resulted in 
replication of virus, as measured by qPCR of viral RNA, functional expression of virus-encoded 
luciferase and release of new infectious virus into the surrounding tissue culture medium (Fig 
4B-E, S2H). Although cultured skin explants do not replicate all aspects of in vivo responses, 
they do enable the study of cell-cell interactions that occur between distinct skin-resident cell 265 
types in the absence of leukocytes that would otherwise be recruited during mosquito-biting 
and virus infection in vivo.  
We applied topical IMQ to the epidermis of explant cultured skin at 1hpi (at the same dosing 
as above for the in vivo studies). Topical IMQ application resulted in robust induction of ISGs 
in skin explants, albeit at lower amounts than that seen in vivo by 24 hours (Fig S2I); perhaps 270 
a consequence of tissue culture media removing some of the applied cream. Importantly, 
application of topical IMQ resulted in a significant (p<0.01),  decrease in viral RNA, virus-
encoded luciferase and a complete block in the release of new virus into the supernatant, for 
both explants derived from resting- and mosquito bitten-skin (Fig 4B-E). The magnitude of 
fold decrease in viral RNA was similar in ex vivo explants derived from resting skin, as 275 
compared to that in mosquito-bitten skin in vivo (Fig. 4F). This suggests that although ISG 
induction was less robust in explants (Fig S2I), it was nonetheless sufficient to reduce virus 
titer. Thus, topical IMQ reduced viral replication irrespective of leukocyte recruitment 
triggered by either infection or by mosquito bite, suggesting tissue-resident cells were 
sufficient for mediating topical IMQ -induced protection from virus in the skin. 280 
We next wanted to define which skin-resident cells were necessary for activating ISG 
expression in response to topical IMQ. Skin-resident leukocytes include populations of gd-T 
cells and ROR-gT innate lymphocytes that are necessary for some inflammatory responses to 
repeated topical IMQ application (36). However, we found that NOD SCID Gamma (NSG) 
mice, which lack all functional lymphocytes and innate lymphoid cells, were similarly protected 285 
from infection at 24hpi by topical IMQ (Fig. 4G). This suggests early skin responses to topical 
IMQ are activated by either stromal cells or non-lymphoid leukocytes, of which 
myelomonocytic cells are the most populous in the dermis. Skin dermis-resident 
myelomonocytic cells are derived  from either bone marrow (BM) precursors (requiring 
expression of chemokine receptor CCR2), or are derived from non-BM embryonic sites of 290 
haematopoiesis (not requiring CCR2 expression) (37). To determine if BM-derived skin 
resident myelomonocytic cells are required to mediate topical IMQ -protection, we infected 
skin explants from ccr2-null and WT mice and treated them with IMQ. Topical IMQ was 
similarly efficacious irrespective of ccr2 status, suggesting that the vast majority of skin-
resident dermal DC and monocytic-derived cells were not required (Fig. 4H). Indeed, IFN and 295 
ISG induction in response to topical IMQ application was similar in ccr2-null skin as compared 
to WT skin (Fig. 4I,J), suggesting that IMQ-responding cells were skin-resident cells not 
derived from myeloid BM-precursors. 
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Together, the above data suggests that the skin-resident cell type responding to topical IMQ 
was either a population of non-BM derived macrophages, mast cells, stromal cells or a 
combination of these. It is not possible to deplete all these cell types; therefore, we 
additionally undertook a comprehensive approach to define responses of all these cell 
populations. This involved analysing the gene expression profile of skin inoculation-site cells 305 
isolated by FACS, to reveal the cell-specific basis for innate immune response to virus and 
separately to topical IMQ (Fig. 5).  
Although skin-resident cells are sufficient to mediate IMQ-responses, this does not necessarily 
exclude a role for mosquito-bite elicited responses at later stages. For this reason, and 
because arboviruses are all naturally transmitted into skin bitten by arthropods, we studied 310 
cellular responses to virus and topical IMQ in mosquito-bitten skin. We adapted a previously-
defined FACS gating strategy (37), to isolate populations of macrophages, dendritic cells, 
stromal cells, and all other CD45+ leukocytes as a bulk population (Fig. S3A,B). These isolated 
populations were then interrogated for their expression of ifna4, ifnb1, isg15 and rsad2 
because they have been previously implicated as key for host responses to alphaviruses (31, 315 
38, 39) and also the prototypic ISG cxcl10.  
The cellular coordination of innate immune responses to virus at the tissue-wide level in 
mosquito-bitten skin are poorly defined. Therefore, we firstly analysed responses of skin cells 
to virus infection alone in the absence of topical IMQ (Fig 5A). At 24hpi, sorted stromal cells 
and macrophages were the only cells that expressed high amounts of virus structural gene 320 
transcript E1, indicative of active replication, while DCs expressed only very low amounts of 
viral RNA (Fig. S3C). This, along with our previous studies (9), suggest that stromal cells and 
macrophages are key targets for viral replication of SFV at mosquito bites in vivo. Importantly, 
the only cell type expressing type I IFN in response to virus were DCs, which was limited to 
ifnb1 only, as no ifna4 was detected. Thus, DCs were the primary initiators of anti-viral ISG 325 
responses at virus-infected mosquito bites. However, dermal DC were present at low numbers 
in the skin at 24hpi, suggesting their total contribution to the tissue-wide IFN response was 
minimal (Fig. S3B). This agrees with our whole tissue analysis that demonstrated little IFN 
expression before 24 hpi described above.  Activated DCs are highly migratory and rapidly 
leave the skin via the lymphatics, which may part explain why skin-wide IFN expression was so 330 
low. In summary, although stromal cells and macrophages exhibited high expression of viral 
RNA they did not make detectable type I IFN. Nonetheless they expressed the ISG rsad2, 
cxcl10 and isg15 by 24hpi (Fig. 5A), presumably in response to DC-expressed IFN cues. All 
other leukocytes included in the bulk sort did not express IFN or upregulate ISG in response 
to virus.  335 
Next, to determine which cells were activated by topical IMQ, mosquito-bitten mouse skin 
was treated with topical IMQ alone (Fig. 5B, Fig. S3E). Crucially, in contrast to virus infection, 
topical IMQ induced ifnb1 expression in both the more populous skin-resident macrophages 
and dermal DC, while stromal cells and all other leukocytes lacked type I IFN transcripts. In 
response, stromal cells substantially upregulated rsad2 and isg15. The ability of this assay to 340 
detect type I IFN transcripts is in contrast to that found in whole skin biopsies where IFN 
expression was not detected (Figure 3). This most likely reflects the enhanced sensitivity that 
is provided by analysing sorted/purified populations of cells.  
As viruses have evolved mechanisms to antagonise IFN signaling we next wanted to 
determine if virus infection modulated this response to topical IMQ. Therefore, we infected 345 
mosquito bites with virus, either with or without topical IMQ application at 1 hpi and assayed 
type I IFN and ISG expression at 24 hpi in each cell type (Fig 5C). Despite the lower titres of 
virus in topical IMQ-treated skin by 24 hpi (and therefore less activation of IFN signalling via 
virus sensing), we found equal or higher fold increases in the expression of both type I IFNs 
and ISG in the macrophage population. ISG upregulation was also more robust in 350 
macrophages, DC and stromal cells, with the exception of rsad2 in DC, suggesting that IMQ-
induced upregulation during virus infection was ISG and cell type-specific. Activation of higher 
IFN expression in macrophages was important for two reasons; firstly, macrophages were 
significantly more numerous in the skin than dermal DC at 24 hpi (Fig. S3B, p<0.001) and 
secondly, they constituted an important source of virus replication in the first 24 hours of 355 
infection (Fig S3C and (9)). IMQ-elicited IFN appeared to be functional, as type I IFN negative 
stromal cells exhibited a significant decrease in viral RNA with topical IMQ treatment by 24hpi, 
as did virus in infected macrophages (Fig. S3C p<0.05).  
Together, this shows that topical IMQ upregulated type I IFN in skin-resident macrophages 
that, in addition to responses of the less frequent dermal DCs, acted to induce ISG expression 360 
and thereby reduce viral replication in the skin. Furthermore, because dermal DC-deficient 
ccr2-null skin (37) was not compromised in its ability to express ISG or reduce virus titres in 
response to topical IMQ, as described above, we suggest that skin-resident macrophages 
alone are sufficient to mediate protection. Thus, based on these associations, it is likely that 
responses by skin-resident macrophages to topical IMQ are sufficient to confer protection 365 
against virus infection. 
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We next wanted to determine whether signals from IMQ-activated macrophages and DCs are 
alone sufficient to confer protection on stromal cells from virus infection and whether this 370 
required cell-to-cell contact. The majority of dermal stromal cells are either fibroblasts or 
keratinocytes, both of which can be experimentally infected with a range of arboviruses (10, 
40, 41), including SFV4 (Fig. 6A-D). Some cultured fibroblasts have been described to express 
a variety of receptors that sense virus, including the IMQ receptor TLR7 (42). However, we 
found that FACS-isolated stromal cells ex vivo lacked detectable TLR7 (Fig. S3D). In addition, 375 
our cultured primary dermal fibroblasts (Fig. 6B) and keratinocytes (Fig. 6E) did not show any 
response to IMQ following SFV infection; IMQ did not protect cells from infection; ISG cxcl10 
expression was not induced (even at high doses, Fig. 6C); and media from fibroblasts pre-
treated with IMQ for 24 hours did not confer protection to other stromal cells from subsequent 
virus infection (Fig. 6D). Thus, both our in vivo and in vitro analyses suggest stromal cells were 380 
not able to respond to IMQ alone.   
To determine if soluble factors from IMQ-stimulated DCs or macrophages could influence the 
susceptibility of primary cultures of skin fibroblasts to infection, primary cultures of leukocytes 
were stimulated with IMQ for 24 hours and their supernatant given to fibroblasts at 1 hpi with 
luciferase-expressing SFV6-Gluc (Fig. 6D). While supernatant from resting leukocytes had no 385 
effect on fibroblast susceptibility to infection, tissue culture supernatant from DC or 
macrophages treated with IMQ protected fibroblasts from infection, as measured by virus-
encoded luciferase. 
As infected myeloid cells and DC are susceptible to arbovirus-encoded anti-IFN mechanisms 
(43, 44), we next determined if infected DC were still able to provide IMQ-induced protection 390 
and trigger an anti-viral state in stromal cells. To do this we used a transwell system in which 
DCs were separated from stromal cells by a cell-impermeable membrane. All cells were 
infected with SFV4(Xho)-EGFP and treated at 1 hpi with either 0.2 µg/ml IMQ or saline control 
(Fig. 6E-H). DC cultures themselves became infected with SFV, exhibiting high level 
expression of viral RNA (Fig 6G). Nonetheless, DC were able to resist infection upon addition 395 
(1hpi) of IMQ and consequently expressed higher amounts of the ISG cxcl10. Importantly, 
while the addition of IMQ alone, or DC alone, had no effect on the ability of co-cultured 
stromal cells to resist infection, the combined presence of both IMQ and DC did protect 
keratinocytes (Fig. 6E-F and Fig S4) and fibroblasts (Fig. 6H). This was evident by a significant 
decrease in viral RNA expression (Fig 6E,H, p<0.05) and by microscopic inspection of the 400 
stromal cell monolayer that otherwise became decimated by 24hpi, with the remaining intact 
cells also positive for virus-encoded eGFP (Fig. 6F, Fig. S4). Protection from virus in stromal 
cells occurred in conjunction with the induction of stromal ISG expression (Fig. 6I). IMQ-
treated keratinocytes only increased IFN and ISG expression with the addition of DCs to the 
transwell insert. Thus, IMQ-induced stromal cell protection from virus occurs in conjunction 405 
with the induction of ISG expression that was licenced by extracellular cues derived from IMQ-
responsive leukocytes.   
 
 s  -
   410 
We finally wanted to determine whether activating IFN pathways by topical IMQ at the skin 
inoculation site could have potential applicability to a variety of genetically distinct 
arboviruses of medical importance. We therefore analysed the ability of topical IMQ to 
modulate the outcome of infection to a relevant representative of each of genetically-distinct 
groups of arboviruses in mice and human skin explants. The prototypic Bunyamwera virus 415 
(BUNV, genus Orthobunyavirus, family Peribunyaviridae, order Bunyavirales), which like SFV is 
also transmitted by Aedes mosquitoes, replicates efficiently at mosquito bites in the skin and 
causes viremia in mice (9). BUNV has well-described potent IFN antagonism (4) and therefore 
may be resistant to topical IMQ treatment. However, when mosquito-bitten BUNV-infected 
inoculation site was treated with topical IMQ at 1hpi, there was a significant decrease in viral 420 
RNA in target tissues (p<0.01 to p<0.05) and blood (p<0.001 to p<0.05) from 24 to 72 hpi (Fig. 
7A-C). Similarly, we determined if topical IMQ could prevent dissemination of arthritogenic 
CHIKV (a medically important pathogen of the Togaviridae family that has caused widespread 
outbreaks of disease) to mouse joints that were remote from the inoculation site (Fig. 7D-G). 
By day 5 post infection, mice treated with topical IMQ 1 hpi exhibited significantly lower 425 
amount of CHIKV RNA (qPCR) and infectious virus in the ankle joints and wrists of the forelimbs 
(Fig. 7D-G and S5, p<0.0001 to p<0.05), irrespective of whether mice were co-inoculated with 
mosquito saliva.  
Finally, to determine if topical IMQ could also reduce viral replication in human skin, we 
cultured explants of freshly biopsied human skin, infected them with virus and treated with 430 
topical IMQ to the epidermis at 1 hpi (Fig. 7H-I). Application of topical IMQ resulted in a 
significant decrease in viral replication for both CHIKV and ZIKV (genus Flavivirus of the family 
Flaviviridae), as measured by viral RNA and also infectious virus at 24 and 48 hpi (p<0.001 to 
p<0.05). Taken together these studies demonstrate that an innate immune agonist that 
primarily targets inoculation-site skin-resident macrophages, has a significant post-exposure 435 
prophylactic effect on the replication and dissemination of a variety of genetically distinct 
medically important viruses.  
 
 
 440 
We demonstrate that innate immune responses to virus in the skin is a limiting factor for 
suppressing subsequent systemic infection. Critically, we show that therapeutic modulation 
of these pathways in the first hours of infection can suppress disease and improve clinical 
outcome in mice. This work therefore identifies the inoculation site as an important site of 
arboviral replication and that skin innate immune virus-sensing pathways must be sufficiently 445 
robust to act as determinants of the clinical course. In addition to the basic biological insights 
that these studies provide, we suggest that therapies that either target IFN induction, or 
alleviate the virus-encoded mechanisms that inhibit IFN, may therefore be efficacious. 
Targeting a common pathway at the inoculation site, as shown here to suppress infection by 
several genetically distinct arboviruses, may circumvent the need to develop multiple species-450 
specific antivirals, as their development and future use remains challenging due to the 
unpredictable nature of arbovirus outbreaks and difficulty associated with reaching an 
accurate and timely clinical diagnosis.  
In this study, we identified the key skin cell types in mice that coordinate anti-viral immune 
responses to virus and those that respond to topical IMQ. We found that skin type I IFN 455 
expression to virus was restricted to the relatively rare DC population. In contrast, 
macrophages and stromal cells could not elicit IFN expression to virus alone, despite a high 
level of viral RNA in these cells. Thus, skin-resident DC are key activators of the type I IFN 
response at the inoculation site to virus. Such specificity may reflect either cell-type specific 
susceptibility to virus-encoded mechanisms to antagonise IFN activation or the particular cell-460 
tropism of our model arbovirus, SFV. 
We suggest that the observed efficacy of our exemplar immune-modulator, topical IMQ 
(Aldara), was explained by activation of dermal macrophages. These cells were not only 
otherwise deficient in their IFN expression in response to virus alone, but also replicate virus 
(9). We found that IFN signalling was key for IMQ-induced protection from virus, while skin-465 
resident macrophages were the only cell type that increased IFN-b in response to IMQ, and 
also that their addition to cultures of skin fibroblast were sufficient to confer IMQ-induced 
protection. We suggest that therapies that specifically target dermal macrophages may 
provide yet enhanced efficacy, for example by increasing retention of the drug within the 
dermis or via delivery within liposomes . Furthermore, as the IMQ receptor TLR7 exhibits a 470 
relatively restricted expression in specific cells, those innate immune agonists that target more 
widely expressed virus-sensing receptors, or their pathways, may further increase efficacy. 
Topical IMQ was no longer efficacious where treatment was delayed for 10 hours in our mouse 
model. We suggest that this timing most likely reflects specific aspects of our model system 
that supports rapid dissemination of SFV, itself a mouse-adapted strain. It is not clear how 475 
these kinetics apply to human infection by mosquito, although it is widely-accepted that virus 
may take considerably longer (several days) to disseminate from human skin to the blood (45). 
This in turn may mean that the window available for post-exposure intervention in humans is 
conveniently longer than that observed in our model, although virus-, host- and environment-
specific factors are likely to define its length. However, because Aedes sp. mosquitoes are 480 
day-biting and their bites are typically visible within minutes, it is possible that there is a 
sufficient time-window for post-exposure prophylactic treatment between infection/biting 
and awareness of a bite/application of cream in humans. Targeting skin responses later during 
infection, e.g. once clinical signs have become apparent, is unlikely to have any effect on the 
severity of infection, as virus wold have already disseminated systemically. Furthermore, it is 485 
important to note that it may not be possible for individuals to notice all mosquito bites 
sufficiently quickly. 
Although the data presented here are primarily derived from studies using mice, we suggest 
that therapeutic intervention at the inoculation site represents a feasible strategy for targeting 
mosquito-borne virus infection that merits further investigation. Putatively, treatment for 490 
either mosquito-, or perhaps also tick- borne virus, could be employed topically in the first 
few hours after an arthropod bite is noticed. We suggest that with refinement, a modified 
form of our exemplar immune-modulator (topical IMQ, Aldara) may have potential as a 
treatment strategy for this globally important disease category. Thus, further work that refines 
the most efficacious method for stimulating IFN responses in macrophages, opens up the 495 
possibility of broadly applicable, cost-effective, therapeutic interventions for arbovirus 
infection.  
We maintained application of topical IMQ for only five hours to a single site, suggesting 
systemic side effects are less likely than with prolonged exposure. However, effective post-
exposure prophylaxis might entail treatment of multiple, discrete, suspected arbovirus-500 
infected mosquito bites, even with e.g. vector repellent strategies employed. Thus, it will be 
important to refine any future formulations such as to render the application of treatment 
practical. However, it should be noted that Aldara has been widely used for many years for a 
variety of dermatological conditions, including in primary care, and is generally well-tolerated 
by patients, even when repeatedly applied at the same site for several weeks (46). Additionally, 505 
our approach would likely entail topical immunomodulation over a smaller surface area than 
those typically treated with Aldara for its licensed indications. Nonethless, this approach may 
involve repeated activation of IFN responses, which even if done at discrete localised sites, 
may come with associated concomitant side effects. Finally, it is noteworthy that outbreaks of 
arbovirus infection are explosive in nature and can be highly seasonal, enabling possible use 510 
of any prophylactic strategies to be more intensively promoted when risk of infection is known 
to be high. Furthermore, it is possible that those patients deemed at higher risk of 
complications following arbovirus infection, such as immunosuppressed individuals, or e.g. 
those that are more susceptible to severe dengue, may particularly benefit from this strategy.  
 515 
 
Study design 
This study was initiated to determine whether anti-viral innate immune response to arbovirus 
at the mosquito bite can be therapeutically manipulated to suppress the subsequent systemic 
course and improve outcome of infection in mice. We investigated mammalian host responses 520 
to representative viruses from three genetically divergent groups of arboviruses. Two of the 
viruses (ZIKV and CHIKV) are medically important emerging arboviruses, whereas the others 
(SFV and BUNV) are model viruses that replicate efficiently in immune competent mice. As 
previously described (9), Ae. aegypti bite sites were infected with mosquito cell culture-
derived virus in a sub-µl volume by hyperfine needle. Infected mosquitoes were not used to 525 
inoculate virus to mice as the inoculum supplied by biting mosquitoes was too variable and 
unpredictable to allow effective comparisons; infected mosquito saliva was used as a co-
inoculum with virus in some studies here.  All experiments involving mice had been subject to 
rigorous review by our local welfare and ethical review committee and additionally approved 
by the UK Home Office (licence PA7CF4E75).  530 
On the basis that immune responses in mice may not always resemble those in humans, we 
also investigated the ability of interventions to suppress infection with the human pathogens 
ZIKV and CHIKV in human skin explants. Human studies were performed following ethical 
approval and in accordance with all applicable regulations (research ethics committee number 
10/H1306/88 and 16/HY/0086).  Sample sizes and end points were selected on the basis of our 535 
published experience with arbovirus infection. Wherever possible, preliminary mouse 
experiments were performed to determine requirements for sample size, considering the 
available resources and ethical use of animals. Female animals (age-matched) were assigned 
randomly to experimental groups. For plaque assays, luciferase assays, and qPCR, samples 
were coded prior to analysis, to limit bias. For qPCR, each result represents the median of 3 540 
or 4 technical replicates of one biological replicate. For plaque assay, viral stocks and 
biological samples was serially diluted and each dilution assayed in duplicate. Biological 
replicates from mice were excluded from analysis if injection of virus inadvertently punctured 
a blood vessel (although this was rare and occurred with a frequency of <1%).  No outliers 
were removed from these studies. Primary data are reported in data file S1. 545 
 
Baby hamster kidney (BHK)-21 cells and C6/36 mosquito cells were grown as previously 
described (9). Mouse leukocytes were derived from bone marrow-precursors, using 10ng/ml 
M-CSF for 6 days (macrophages); 20ng/ml GM-CSF for 6 days or 200 ng/ml Flt3L for 10 days 
(dendritic cells). C57Bl/6-derived primary keratinocytes (Cell biologics) were grown in 550 
complete epithelial cell media as per manufacturerÕs instructions. Skin fibroblasts were 
derived from adult C57Bl/6 dermis, digested with collagenase D (1 mg/ml), dispase II (0.5 
mg/ml), and DNAse (0.1 mg/ml) in HBSS to release cells and adherent fibroblasts grown for 
12 days in complete DMEM.  
 555 
The pCMV-SFV4 and pCMV-SFV6 backbone for production of SFV has been previously 
described (25, 47). The full-length infectious cDNA clone of SFV4, was engineered by Peter 
Liljestrm (Karolinska Institutet) and was used to construct a stabilized infectious SFV plasmid, 
pCMV-SFV4 (47, 48). SFV6 is a copy of non-mouse adapted SFV L10 (a polyclonal virulent 
isolate), derived by making 6 nonsynonymous nucleotide changes to SFV4. The derived virus, 560 
SFV6, generates a high-titer viremia in mice, is efficiently neuroinvasive and highly virulent 
(25). The EGFP marker gene was inserted into the C- terminal region of SFV nsP3 via a 
naturally-occurring XhoI site. mCherry and Gaussia luciferase (Gluc) were separately inserted 
as a cassette under the control of a duplicated sub-genomic protomer 3Õ with resulting viruses 
referred to here as SFV6-mCherry and SFV6-Gluc (49). Plasmids were electroporated into BHK-565 
21 cells to generate infectious virus. SFV clones that have been genetically altered in this way 
are stable and there is no evidence of virus attenuation or genetic instability (50). A such, the 
use of these reporter viruses allowed the replication, dissemination and localisation of SFV to 
be studied in high detail. SFV4 is the prototypic, less virulent strain of the virus, whereas SFV6 
is a copy of a virulent strain (25). Both strains cause disease in mice when inoculated in the skin 570 
at a mosquito bite (9).  
Wild type BUNV was derived as previously described (51). A low passage wild type ZIKV isolate 
(52) was derived from a patient displaying classical disease symptoms in Recife (ZIKV PE243) 
and has been sequenced, kindly supplied by Prof Alain Kohl (MRC-University of Glasgow 
Centre for Virus research). In CHIKV mouse experiments, CHIKV Indian Ocean strain 899 575 
(FJ959103.1) was used (Prof. C. Drosten, University of Bonn, Germany) (53).  For human explant 
studies, CHIKV was made from the infectious clone derived from the LR2006_OPY1 isolate 
(DQ443544). These strains were chosen as they have both been passaged only a few times 
since isolation and likely represent wild type circulating virus. We estimate that the CHIKV and 
ZIKV used here has not been passaged more than 5 times in total since isolation. In all cases, 580 
viruses were grown once in BHK-21 cells, then passaged once in C6/36 Aedes mosquito cells 
and titrated prior to use, as mosquito cell derived virus has distinct glycosylation and because 
insect cells impose distinct evolutionary constraints on viral progeny (54). SFV4 and SFV6 were 
used at passage 2.  
 585 
In all cases, results have been generated by infecting mice with the same passage of virus. 
Unless otherwise specified, all mice were 6-8-week-old wild type mice (C57bl/6J). C57bl/6J  
and Nod-SCID gamma (NSG) mice were derived from a locally bred-colony maintained in a 
pathogen-free facility, in filter-topped cages and maintained in accordance with local and 
governmental regulations. To prevent genetic drift, mice were have been re-derived using 590 
externally-supplied mice (Charles River). Ccr2-deficient mice were originally obtained from the 
Jackson Laboratory (stock number 004999). Ifnar1-deficient and wild type (WT) counterparts 
on a 129S7/SvEvBrdBkl-Hprtb-m2 background (B&K Universal) were maintained in Tecniplast 
1284 L Blue line IVC cages at Biological Services, University of Glasgow. All mice had a 12 h 
light/dark cycle and provided ad libitum with sterile food and water. 595 
 
We used our previously established model of arbovirus infection at mosquito bites (9). This 
model was specifically developed to consistently model natural infection by arbovirus, 
including: mimicking the same dose delivered by mosquitoes (between 100 and 100,000 PFU 
for alphaviruses), using mosquito-cell derived virus, injecting small 1 µl inoculum volume, and 600 
by including the presence of a mosquito bite at the site of inoculation. To ensure mosquitoes 
bit a defined area of skin (upper side of the left foot), anesthetized mice were placed  for up 
to ten minutes onto a mosquito cage containing Ae. aegypti mosquitoes (locally bred colony 
derived from the Liverpool strain) as previously described (9). Biting was restricted to defined 
area of the left foot by covering all other mouse skin with an impenetrable barrier. Bitten skin 605 
(3-5 mosquito bites/foot) was injected with virus in a 1 μl volume into the skin, using either 250 
PFU SFV6, 1x10^4 PFU SFV4, or 2.5x10^4 PFU BUNV. These doses represent those that are 
known to initiate high titre viremia by 24 hpi and, for SFV, clinical signs within days post 
infection. Total RNA input (copy number) from inoculum is roughly 10-fold higher than PFU 
(55). For survival curves, mice were monitored closely and culled when they reached more than 610 
three clinically defined end-points of disease. Clinical signs included; body weight loss >10%; 
subdued behaviour when provoked; hunching; convulsions; limb paralysis; prostration 
>1hour; and vocalisation. For CHIKV infection of mice, 3-4 week-old mice were infected by 
s.c. injection of 106 PFU of CHIKV in the hind-left foot pad with or without Aedes aegypti 
mosquito saliva.  615 
 
Washed male rabbit blood (ENVIGO) was mixed with 2mM ATP (ThermoScientific) and 
7.8*10^7 PFU/ml SFV4. Blood was loaded into a hemotek feeder (HEMOTEk) and placed on 
cages containing Ae. aegypti mosquitoes for 45 minutes to allow mosquitoes to feed. Fully 
engorged female mosquitoes were then transferred into boxes and maintained at 28¡C, 80% 620 
humidity for 7 days. Mosquito saliva was extracted in oil from salivating mosquitoes and 
corresponding individual mosquito heads were harvested and submerged in TRIzol (Life 
Technologies). Saliva from groups of 5 mosquitoes were pooled together and stored at -80¡C. 
RNA from mosquito heads was extracted using PureLink RNA micro columns as per 
manufacturerÕs instructions (Life Technologies).  Mosquito heads were homogenised in TRIzol  625 
using a precellys 24 tissue homogeniser (Bertin Instruments) with glass beads (VWR), followed 
by purification using PureLink micro columns (Life Technologies). RNA was converted into 
cDNA using the High Capacity RNA-to-cDNA kit (Life Technologies). Expression of SFV E1 
gene was undertaken using custom designed SYBR-green based qPCR assay using PerfeCTa 
(Quanta). Samples were analysed using ΔΔCT against negative control mosquito heads 630 
(CT>35). Saliva groups from SFV E1 positive mosquito heads were then pooled and UV 
inactivated for 10 minutes to remove virus and then mixed with a defined dose of 10,000 PFU 
SFV4 for inoculation into mouse skin.  
 
Anesthetized mice were injected with either 6μg poly(I:C), poly(dA:dT) or IMQ (Invivogen) into 635 
skin as a 4µl aqueous volume using Hamilton syringes, at the same site as virus infection (using 
upper skin of left foot (9)). Poly (I:C) and poly (dA:dT) were purchased pre-complexed with 
transfection reagent Lyovec. 2mg topical IMQ (Aldara, 5% w/w IMQ; 25% w/w isostearic acid) 
was applied to the site of virus inoculation (upper side of left foot). In most cases, because 
topical IMQ is a cream that can become removed by cage bedding, it was re-applied once at 640 
6 hpi to maintain dosing. Although it is difficult to define the exact dose of IMQ provided 
using topical application of cream, previous studies have shown that dosing results in limited 
systemic absorption, with IMQ concentration peaking at 0.4 ng/ml blood in humans (33), with 
most being retained in the absorbent stratum corneum (the outer dead keratinized layer) or 
otherwise removed by external processes.   645 
S  
For human explants, informed consent was obtained from 16 volunteer donors, and skin 
sourced from areas that were relatively protected from environmental insult and had no 
obvious lesions (upper inner arm). Human studies were performed following ethical approval 
and in accordance to all applicable regulations.  For mouse studies, skin was derived from 650 
either resting skin, or from mosquito-bitten skin (biopsied at 4 hour post bite) . For both human 
and mouse studies, skin was dissected to remove sub-dermal tissues, to leave dermis 
exposed, and immediately infected with virus by placing lower dermis into virus-containing 
solution (0.75% BSA in PBS,  PBSA) for one hour. Explants were then washed in saline and the 
epidermal surface of the skin explant was briefly dried. Similar to our mouse-based in vivo 655 
studies, 2mg topical IMQ (Aldara) was applied topically to the epidermis (at 1 hpi) until 
absorbed. Explants were then cultured in 24 well plates containing complete DMEM media at 
37oC/5% CO2 for up to 48 hours.  
G  
Viral RNA and hosts gene transcripts were quantified by qRT-PCR and infectious virus by end-660 
point titration, as described previously (53). Tissue generated up to 100µg of total RNA, of 
which 1µg of RNA was used to create cDNA, of which 1% was used per qPCR assay (10 ng 
RNA equivalent). qPCR primers for SFV and CHIKV amplified a section of E1 and primers for 
BUNV targeted segment M (9), while primers for ZIKV amplified a section of the env gene. For 
SFV, CHIKV and ZIKV, qPCR assays measured the sum value of both genome and sub-665 
genomic RNA.  
F   
For FACS, skin tissue samples were enzymatically digested with collagenase D (1 mg/ml), 
dispase II (0.5 mg/ml), and DNAse (0.1 mg/ml) in HBSS for 50 minutes at 37oC. Enzymes were 
quenched with serum, cells washed, treated with FcR block (Miltenyi Biotec) and stained with 670 
antibodies and a viability dye (9). Cells were analysed on a CytoFLEX (Beckman Coulter Life 
Sciences). For cell sorting, skin was digested and stained on ice in presence of a transcriptional 
inhibitor (actinomycin D) and sorted to 90-100% purity using an Influx cell sorter (BD). See fig. 
S3 for the gating strategy. 
 675 
Tissues were fixed in 4% methanol-free paraformaldehyde (Thermo Scientific) then 
dehydrated in an increasing concentration of sucrose. Tissue was embedded in Optimal 
Cutting Temperature (OCT) compound (Agar Scientific) and sectioned. Tissue sections were 
stained with DAPI mounting media and imaged on a Zeiss Axioskop.  
 680 
Data were analyzed using Prism Version 7 software. Copy numbers of viral RNA and infectious 
titres from virus-infected mice were not normally distributed (with data points often spread 
over orders of magnitude) and were accordingly analyzed using the non-parametric based 
tests Mann-Whitney or Kruskal-Wallis test with DunnÕs multiple comparison test where 
appropriate, unless otherwise stated in figure legends. All such column plots show the median 685 
value +/- interquartile range. Where data were normally distributed (as determined by using 
either the Shapiro-Wilk test or by simple visual inspection), data were analyzed using ANOVA 
with Holm-SidakÕs multiple comparison test and plotted with mean values. Survival curves 
were analyzed using the logrank (Mantel Cox) test. All plots have statistical significance 
indicated *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns=not significant.  690 
 
 
Fig. S1. Pre-exposure of skin to topical IMQ increased host resistance to infection with SFV4.  
Fig. S2. Type I IFN and ISG expression in skin and draining LN following IMQ application.  
Fig. S3. Gene expression analysis of skin inoculation site-derived FACS isolated cells 695 
Fig. S4. IMQ-mediated protection against virus infection in keratinocytes is dependent on 
help from leukocytes.  
Fig. S5. Topical IMQ prevents systemic dissemination of CHIKV to joint tissue remote from 
inoculation site. 
Data file S1. Primary data 700 
  
1. S. C. Weaver, C. Charlier, N. Vasilakis, M. Lecuit, Zika, Chikungunya, and Other Emerging 
Vector-Borne Viral Diseases, Annu. Rev. Med. , 395Ð408 (2018). 
2. M. G. Guzman, E. Harris, Dengue, Lancet , 453Ð465 (2015). 
3. E. A. Gould, T. Solomon, Pathogenic flaviviruses., Lancet , 500Ð509 (2008). 705 
4. R. M. Elliott, Orthobunyaviruses: recent genetic and structural insights., Nat. Rev. 
Microbiol. , 673Ð685 (2014). 
5. A. M. Powers, A. C. Brault, Y. Shirako, E. G. Strauss, W. Kang, J. H. Strauss, S. C. Weaver, 
Evolutionary relationships and systematics of the alphaviruses., J. Virol. , 10118Ð10131 
(2001). 710 
6. A. J. Rodriguez-Morales, W. E. Villamil-Gmez, C. Franco-Paredes, The arboviral burden 
of disease caused by co-circulation and co-infection of dengue, chikungunya and Zika in the 
Americas, Travel Med. Infect. Dis. , 177Ð179 (2016). 
7. N. M. Ferguson, D. A. T. Cummings, S. Cauchemez, C. Fraser, S. Riley, A. Meeyai, S. 
Iamsirithaworn, D. S. Burke, Strategies for containing an emerging influenza pandemic in 715 
Southeast Asia, Nature , 209Ð214 (2005). 
8. E. A. Gould, S. T. Higgs, Impact of climate change and other factors on emerging 
arbovirus diseases, Trans. R. Soc. Trop. Med. Hyg. , 109Ð121 (2009). 
9. M. Pingen, S. R. Bryden, E. Pondeville, E. Schnettler, A. Kohl, A. Merits, J. K. Fazakerley, G. 
J. Graham, C. S. McKimmie, Host Inflammatory Response to Mosquito Bites Enhances the 720 
Severity of Arbovirus Infection, Immunity , 1455Ð1469 (2016). 
10. M. Pingen, M. A. Schmid, E. Harris, C. S. McKimmie, Mosquito Biting Modulates Skin 
Response to Virus Infection., Trends Parasitol. , 645Ð657 (2017). 
11. M. J. Conway, T. M. Colpitts, E. Fikrig, Role of the Vector in Arbovirus Transmission., 
Annu. Rev. Virol. 1, 71Ð88 (2014). 725 
12. B. S. Schneider, S. T. Higgs, The enhancement of arbovirus transmission and disease by 
mosquito saliva is associated with modulation of the host immune response, Trans. R. Soc. 
Trop. Med. Hyg. , 400Ð408 (2008). 
13. L. M. Styer, P. Y. Lim, K. L. Louie, R. G. Albright, L. D. Kramer, K. A. Bernard, Mosquito 
Saliva Causes Enhancement of West Nile Virus Infection in Mice, J. Virol. , 1517Ð1527 730 
(2011). 
14. J. Cox, J. Mota, S. Sukupolvi-Petty, M. S. Diamond, R. Rico-Hesse, Mosquito bite delivery 
of dengue virus enhances immunogenicity and pathogenesis in humanized mice., J. Virol. 
, 7637Ð7649 (2012). 
15. D. Olagnier, F. E. M. Scholte, C. Chiang, I. C. Albulescu, C. Nichols, Z. He, R. Lin, E. J. 735 
Snijder, M. J. van Hemert, J. Hiscott, Inhibition of Dengue and Chikungunya Virus Infections 
by RIG-I-Mediated Type I Interferon-Independent Stimulation of the Innate Antiviral 
Response, J. Virol. , 4180Ð4194 (2014). 
16. W. M. Schneider, M. D. Chevillotte, C. M. Rice, Interferon-Stimulated Genes: A Complex 
Web of Host Defenses, Annu. Rev. Immunol. , 513Ð545 (2014). 740 
17. J. W. Schoggins, S. J. Wilson, M. Panis, M. Y. Murphy, C. T. Jones, P. Bieniasz, C. M. Rice, 
A diverse range of gene products are effectors of the type i interferon antiviral response, 
Nature , 481Ð485 (2011). 
18. T. M. Sali, K. M. Pryke, J. Abraham, A. Liu, I. Archer, R. Broeckel, J. A. Staverosky, J. L. 
Smith, A. Al-Shammari, L. Amsler, K. Sheridan, A. Nilsen, D. N. Streblow, V. R. DeFilippis, S. 745 
Cherry, Ed. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral 
Activity Against Emerging Alphaviruses, PLoS Pathog. , e1005324-30 (2015). 
19. M. G. Ghany, D. B. Strader, D. L. Thomas, L. B. Seeff, Diagnosis, management, and 
treatment of hepatitis C: An update, Hepatology , 1335Ð1374 (2009). 
20. J. D. Morrey, C. W. Day, J. G. Julander, L. M. Blatt, D. F. Smee, R. W. Sidwell, Effect of 750 
interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal 
models., Antivir. Chem. &amp; Chemother. , 101Ð109 (2004). 
21. T. Solomon, D. NM, B. Wills, R. Kneen, M. Gainsborough, D. TV, T. TTN, L. HT, K. VC, V. 
DW, W. NJ, F. JJ, T. Solomon, N. M. Dung, B. Wills, R. Kneen, M. Gainsborough, T. V. Diet, 
T. T. N. Thuy, H. T. Loan, Interferon alfa-2a in Japanese encephalitis: a randomised double-755 
blind placebo-controlled trial., Lancet , 821Ð826 (2003). 
22. R. A. Lukaszewski, T. J. G. Brooks, Pegylated Alpha Interferon Is an Effective Treatment 
for Virulent Venezuelan Equine Encephalitis Virus and Has Profound Effects on the Host 
Immune Response to Infection, J. Virol. , 5006Ð5015 (2000). 
23. M. Rodrguez-Pulido, M. A. Martn-Acebes, E. Escribano-Romero, A. B. Blzquez, F. 760 
Sobrino, B. Borrego, M. Siz, J. C. Saiz, Protection against West Nile Virus Infection in Mice 
after Inoculation with Type I Interferon-Inducing RNA Transcripts, PLoS One 7, 1Ð8 (2012). 
24. A. Nazmi, S. Mukherjee, K. Kundu, K. Dutta, A. Mahadevan, S. K. Shankar, A. Basu, TLR7 
is a key regulator of innate immunity against Japanese encephalitis virus infection, 
Neurobiol. Dis. , 235Ð247 (2014). 765 
25. M. C. Ferguson, S. Saul, R. Fragkoudis, S. Weisheit, J. Cox, A. Patabendige, K. Sherwood, 
M. Watson, A. Merits, J. K. Fazakerley, S. Perlman, Ed. Ability of the Encephalitic Arbovirus 
Semliki Forest Virus To Cross the Blood-Brain Barrier Is Determined by the Charge of the E2 
Glycoprotein., J. Virol. , 7536Ð7549 (2015). 
26. A. N. N. M. Powers, A. C. Brault, Y. Shirako, G. Ellen, W. Kang, J. H. Strauss, C. Scott, A. 770 
N. N. M. Powers, E. G. Strauss, Evolutionary Relationships and Systematics of the 
Alphaviruses Evolutionary Relationships and Systematics of the Alphaviruses, J. Virol. , 
10118Ð10131 (2001). 
27. M. A. Schmid, D. R. Glasner, S. Shah, D. Michlmayr, L. D. Kramer, E. Harris, Mosquito 
Saliva Increases Endothelial Permeability in the Skin, Immune Cell Migration, and Dengue 775 
Pathogenesis during Antibody-Dependent Enhancement, PLoS Pathog. , e1005676 (2016). 
28. S. Sim, J. L. Ramirez, G. Dimopoulos, Dengue virus infection of the aedes aegypti salivary 
gland and chemosensory apparatus induces genes that modulate infection and blood-
feeding behavior, PLoS Pathog. 8 (2012), doi:10.1371/journal.ppat.1002631. 
29. A. Walter, M. Schfer, V. Cecconi, C. Matter, M. Urosevic-Maiwald, B. Belloni, N. 780 
Schnewolf, R. Dummer, W. Bloch, S. Werner, H. D. Beer, A. Knuth, M. Van Den Broek, 
Aldara activates TLR7-independent immune defence, Nat. Commun. 4, 1Ð13 (2013). 
30. Y. Kan, T. Okabayashi, S. -i. Yokota, S. Yamamoto, N. Fujii, T. Yamashita, Imiquimod 
Suppresses Propagation of Herpes Simplex Virus 1 by Upregulation of Cystatin A via the 
Adenosine Receptor A1 Pathway, J. Virol. , 10338Ð10346 (2012). 785 
31. K. S. Carpentier, T. E. Morrison, Innate immune control of alphavirus infection, Curr. 
Opin. Virol. , 53Ð60 (2018). 
32. M. B. Iversen, L. S. Reinert, M. K. Thomsen, I. Bagdonaite, R. Nandakumar, N. 
Cheshenko, T. Prabakaran, S. Y. Vakhrushev, M. Krzyzowska, S. K. Kratholm, F. Ruiz-Perez, S. 
V Petersen, S. Goriely, B. M. Bibby, K. Eriksson, J. Ruland, A. R. Thomsen, B. C. Herold, H. H. 790 
Wandall, S. Frische, C. K. Holm, S. R. Paludan, An innate antiviral pathway acting before 
interferons at epithelial surfaces, Nat. Immunol. , 150Ð158 (2015). 
33. 3M, ALDARAPharmacokinetics (2004) (available at 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20723s016lbl.pdf). 
34. C. Handfield, J. Kwock, A. S. MacLeod, Innate Antiviral Immunity in the Skin, Trends 795 
Immunol. , 328Ð340 (2018). 
35. L.-J. juan Zhang, G. L. Sen, N. L. Ward, A. Johnston, K. Chun, Y. Chen, C. Adase, J. A. 
Sanford, N. Gao, M. Chensee, E. Sato, Y. Fritz, J. Baliwag, M. R. Williams, T. Hata, R. L. Gallo, 
Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal 
Keratinocytes during Skin Injury, Immunity , 119Ð130 (2016). 800 
36. S. Pantelyushin, S. Haak, B. Ingold, P. Kulig, F. L. Heppner, A. Alexander, A. a Navarini, B. 
Becher, Brief report Ror γ t + innate lymphocytes and γδ T cells initiate psoriasiform plaque 
formation in mice, J. Clin. Invest. , 2252Ð2256 (2012). 
37. S. Tamoutounour, M. Guilliams, F. Montanana Sanchis, H. Liu, D. Terhorst, C. Malosse, E. 
Pollet, L. Ardouin, H. Luche, C. Sanchez, M. Dalod, B. Malissen, S. Henri, Origins and 805 
functional specialization of macrophages and of conventional and monocyte-derived 
dendritic cells in mouse skin., Immunity , 925Ð938 (2013). 
38. S. W. Werneke, C. Schilte, A. Rohatgi, K. J. Monte, A. Michault, F. Arenzana-Seisdedos, 
D. L. Vanlandingham, S. Higgs, A. Fontanet, M. L. Albert, D. J. Lenschow, ISG15 Is Critical in 
the Control of Chikungunya Virus Infection Independent of UbE1L Mediated Conjugation., 810 
PLoS Pathog. 7, e1002322 (2011). 
39. T.-S. S. Teng, S.-S. S. Foo, D. Simamarta, F.-M. M. Lum, T.-H. H. Teo, A. Lulla, N. K. W. W. 
Yeo, E. G. L. L. Koh, A. Chow, Y.-S. S. Leo, A. Merits, K.-C. C. Chin, L. F. P. P. Ng, Viperin 
restricts chikungunya virus replication and pathology, J. Clin. Invest. , 4447Ð4460 (2012). 
40. R. Hamel, O. Dejarnac, S. Wichit, P. Ekchariyawat, A. Neyret, N. Luplertlop, M. Perera-815 
Lecoin, P. Surasombatpattana, L. Talignani, F. Thomas, V.-M. Cao-Lormeau, V. Choumet, L. 
Briant, P. Desprs, A. Amara, H. Yssel, D. Miss, M. S. Diamond, Ed. Biology of Zika Virus 
Infection in Human Skin Cells., J. Virol. , 8880Ð8896 (2015). 
41. P.-Y. Lim, M. J. Behr, C. M. Chadwick, P.-Y. Shi, K. A. Bernard, Keratinocytes are cell 
targets of West Nile virus in vivo., J. Virol. , 5197Ð5201 (2011). 820 
42. E. A. Kurt-Jones, F. Sandor, Y. Ortiz, G. N. Bowen, S. L. Counter, T. C. Wang, R. W. 
Finberg, Use of murine embryonic fibroblasts to define Toll-like receptor activation and 
specificity, J. Endotoxin Res. , 419Ð424 (2004). 
43. S. Pagni, A. Fernandez-Sesma, Evasion of the human innate immune system by dengue 
virusImmunol. Res. , 152Ð159 (2012). 825 
44. M. A. Schmid, M. S. Diamond, E. Harris, Dendritic cells in dengue virus infection: targets 
of virus replication and mediators of immunity., Front. Immunol. 5, 647 (2014). 
45. O. Schwartz, M. L. Albert, Biology and pathogenesis of chikungunya virus., Nat. Rev. 
Microbiol. 8, 491Ð500 (2010). 
46. N. Jetter, N. Chandan, S. Wang, M. Tsoukas, Field Cancerization Therapies for 830 
Management of Actinic Keratosis: A Narrative Review, Am. J. Clin. Dermatol. , 543Ð557 
(2018). 
47. L. Ulper, I. Sarand, K. Rausalu, A. Merits, Construction, properties, and potential 
application of infectious plasmids containing Semliki Forest virus full-length cDNA with an 
inserted intron., J. Virol. Methods , 265Ð270 (2008). 835 
48. P. Liljestrm, S. Lusa, D. Huylebroeck, H. Garoff, In vitro mutagenesis of a full-length 
cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein 
modulates virus release., J. Virol. , 4107Ð13 (1991). 
49. J. Rodriguez-Andres, S. Rani, M. Varjak, M. E. Chase-Topping, M. H. Beck, M. C. 
Ferguson, E. Schnettler, R. Fragkoudis, G. Barry, A. Merits, J. K. Fazakerley, M. R. Strand, A. 840 
Kohl, K. D. Vernick, Ed. Phenoloxidase activity acts as a mosquito innate immune response 
against infection with Semliki Forest virus., PLoS Pathog. 8, e1002977 (2012). 
50. G. Balistreri, P. Horvath, C. Schweingruber, D. Znd, G. McInerney, A. Merits, O. 
Mhlemann, C. Azzalin, A. Helenius, The host nonsense-mediated mRNA decay pathway 
restricts mammalian RNA virus replication, Cell Host Microbe , 403Ð411 (2014). 845 
51.  a Bridgen, F. Weber, J. K. Fazakerley, R. M. Elliott, Bunyamwera bunyavirus nonstructural 
protein NSs is a nonessential gene product that contributes to viral pathogenesis., Proc. 
Natl. Acad. Sci. U. S. A. , 664Ð669 (2001). 
52. C. L. Donald, B. Brennan, S. L. Cumberworth, V. V Rezelj, J. J. Clark, M. T. Cordeiro, R. 
Freitas de Oliveira Frana, L. J. Pena, G. S. Wilkie, A. Da Silva Filipe, C. Davis, J. Hughes, M. 850 
Varjak, M. Selinger, L. Zuvanov, A. M. Owsianka, A. H. Patel, J. McLauchlan, B. D. 
Lindenbach, G. Fall, A. A. Sall, R. Biek, J. Rehwinkel, E. Schnettler, A. Kohl, Full Genome 
Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil., PLoS 
Negl. Trop. Dis. , e0005048 (2016). 
53. R. Abdelnabi, D. Jochmans, E. Verbeken, J. Neyts, L. Delang, Antiviral treatment 855 
efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not 
during the chronic phase of the infection, Antiviral Res. , 113Ð117 (2018). 
54. L. A. Moser, B. T. Boylan, F. R. Moreira, L. J. Myers, E. L. Svenson, N. B. Fedorova, B. E. 
Pickett, K. A. Bernard, Growth and adaptation of Zika virus in mammalian and mosquito 
cells, PLoS Negl. Trop. Dis.  (2018), doi:10.1371/journal.pntd.0006880. 860 
55. D. Michlmayr, C. S. McKimmie, M. Pingen, B. Haxton, K. Mansfield, N. Johnson, A. R. 
Fooks, G. J. Graham, Defining the chemokine basis for leukocyte recruitment during viral 
encephalitis, J. Virol. , 9553Ð9567 (2014). 
 
 865 
We thank Carolien De Keyzer for assistance with the CHIKV mice studies; the University of 
Leeds Faculty of Medicine & Health Flow Cytometry and Imaging Facilities; Sandra Terry for 
assistance with mosquito culture; the University of Leeds St JamesÕ Biomedical Services, 
Gillian Cardwell and the University of Glasgow Biological services for assistance with mouse 
studies. We are grateful to Nurse Eileen OÕGrade, Dr Benjamin Walker and Dr Philips Laws for 870 
their support in obtaining human skin biopsies. 
: provided by BBSRC DTP PhD fellowship to SRB and CSM; Wellcome Trust Seed 
Award in Science (108227/B/15/Z); The Royal Society research grant (RGS\R1\191390); and the 
University of Leeds UAF to CSM; Wellcome Trust investigator award, MRC programme and a 
Wolfson Royal Society Merit Award to GJG; MRC core funding MC_UU_12014/8 to EP; Fund 875 
for Scientific Research (FWO) Flanders individual credit (1522918N) to LD and FWO PhD 
fellowship (1S21918N) to SJ; and an MRC grant MR/NO1054X/1 to AT.  
Author contributions: 
Conceptualization;  SRB, MP, KS, CSM. 
Funding acquisition; SRB, GJG, LD, SJ, AT, CSM. 880 
Investigation; SRB, MP, DAL, JMil, SJ, RA, EP, JMaj, MM, HK, MV, KS, CSM. 
Methodology; SRB, EP, KS, CSM. 
Project administration; LD, AT, EP, CSM.  
Resources; EP, AT, AM, JE, GJG, KS. 
Supervision; LD, EP, AT, CSM. 885 
Writing Ð original draft; CSM.  
Writing Ð review & editing; SRB, MP, LD, KS, CSM. 
Competing interests: none declared.  
Data and materials availability: All data associated with this study are available in the paper or 
the supplementary materials.  890 
  
 
(A-D) Mice were infected subcutaneously (s.c.) with 250 plaque forming units (PFU) SFV6 in the 895 
upper skin of the left foot. Copy number of host (A) ifnb1, (B) cxcl10 (C) ifng (D) cxcl9 and 18S 
RNA in skin and draining popliteal lymph node (dLN) was determined by qPCR at various 
timepoints. 
(E-K) 1h prior to infection with SFV6 viruses, mice were pretreated with a single 2mg topical 
administration of IMQ, or injected s.c. with 6μg of either; aqueous IMQ, poly(dA:dT) or 900 
poly(I:C). (E-G) At 24hpi, copy number of SFV RNA and host 18S was determined by qPCR at 
24 hpi (E,F) and virus titers in the serum quantified by plaque assay (G). Non-draining LN was 
the popliteal LN contralateral to infection (n=6). (H-K) Survival of mice was assessed when 
defined clinical endpoints were reached (n=10). PID=post infection day.  
Groups that were significantly different to 0 h (A-D) or to SFV infection alone (E-K) are marked; 905 
*p<0.05, **p<0.01, ***p<0.001, ns=not significant (Kruskal-Wallis and logrank (Mantel Cox) 
test). 
 
-
 910 
(A-D) Mosquito-bitten mouse skin was infected with 250 PFU SFV6 and treated with topical 
IMQ at 1 hpi (with one re-application at 6hpi) or left untreated. (A) SFV RNA and host 18S were 
quantified by qPCR at 24hpi (n=7). (B) Plaque assay of serum at 24hpi (n=7). (C) Survival of 
mice (n=10). (D) Mid-sagittal sections of the brain from mice (n=5) infected with SFV6-mCherry 
(red) stained with DAPI (blue); upper composite image was assembled from multiple 915 
photographs, while lower images show typical individual images at higher magnification.  
(E-G) Mosquito-bitten mouse skin was infected with 10 000 PFU SFV4 and treated with topical 
IMQ at 1 hpi (with one re-application at 6hpi) or left untreated. (E) SFV RNA and host 18S were 
quantified by qPCR at 24hpi. (F) Serum virus quantified by plaque assay (n=6). (G) Survival of 
mice (n=11).  920 
(H) Mosquito-bitten mouse skin was infected with 10 000 PFU SFV4 and treated with topical 
IMQ at at either 5 or 10 hpi. SFV RNA and host 18S were quantified by qPCR at 24hpi. (n=5-6)  
(I) Mosquito-bitten mouse skin was infected with 250 PFU SFV6 and then either left; untreated; 
treated with topical IMQ at 1 hpi (with one re-application at 6hpi); or similarly treated with 
topical IMQ and residual cream removed by an aqueous-detergent wash 30 minutes after 925 
second dosing; or administered as an oral gavage of topical IMQ (10% of total dose in water) 
n=6. 
*p<0.05, **p<0.01, ***p<0.001, ****(p<0.0001) ns=not significant (Mann-Whitney, Kruskal-
Wallis or logrank (Mantel Cox) test). 
 930 
 
(A) Mosquito-bitten skin was treated with a single topical application of IMQ. Fold change 
gene expression of ISG in skin was determined by qPCR at 24h post treatment compared to 
untreated controls (n=4).  
(B) ifnar1 -/- mice and syngeneic wild type controls were treated with a single 2mg application 935 
of topical IMQ. Copy number of host ISG and 18S RNA were determined by qPCR at 24h post 
treatment (n=10). 
(C,D) Mosquito-bitten ifnar1 -/- skin (n=5) was infected with 250 PFU SFV6 and treated with 
topical IMQ at 1 hpi (with one re-application at 6hpi) or left untreated. (C) SFV RNA and host 
18S quantified by qPCR at 24hpi. (D) Serum virus quantified by plaque assay.  940 
(E) Mosquito-bitten WT mouse skin was infected with 250 PFU SFV6 and then treated with 
either topical IMQ at 1 hpi, or control cream (25% w/v isostearic acid), with one re-application 
of each at 6hpi. SFV RNA and host 18S was determined by qPCR at 24 hpi (n=7-8).  
(F) Mice were bitten with mosquitoes and the site treated with a single topical application of 
IMQ. Fold change gene expression of ISG in dLN was determined by qPCR at 24h post 945 
treatment compared to untreated controls (n=4). 
(G)  Mosquito-bitten WT mice were treated with topical IMQ and ifnb1 determined by qPCR 
at 24 h (n=5-12). Each graph represents a separate experiments.  
*p<0.05, **p<0.01, ****p<0.0001, ns=not significant (Mann-Whitney and Kruskal-Wallis test). 
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-  
(A) Mosquito-bitten mouse skin was infected with 250 PFU SFV6. At 24 hpi, skin from the 
inoculation site was digested to release cells and numbers of pDCs (CD45+ CD11c+ SiglecH+) 
quantified by FACS per 105 live cells. 
(B-E) Mosquito-bitten skin, at 4 hours post bite, or resting mouse skin, was biopsied and 955 
resulting 6mm skin explants infected ex vivo with 1x 105 PFU SFV6-Gluc. At 1 hpi, the explants 
were removed from the media, briefly dried, and the epidermis treated with a single 
application of topical IMQ. Treated explants were then placed resting in tissue culture media 
and at 24hpi: (B) copy numbers of SFV RNA were determined by qPCR, (C) virus titers in the 
media quantified by plaque assay (n=6), and (D) virus-encoded Gluc assayed (n=6). (E) SFV 960 
RNA were also quantified by qPCR in skin explants at 48 hpi.  
(F) Mice were either infected in vivo at mosquito bites with or without a single application of 
topical IMQ (at 1 hpi), or 6mm explants derived from resting skin (with no associated bite-
recruited leukocytes were infected with 250 PFU SFV6 ex vivo by needle and then treated with 
a single application topical IMQ (at 1 hpi). Copy number of SFV RNA and host 18S was 965 
determined by qPCR at 24 hpi and compared to respective untreated infected controls (n=6-
7). 
(G) Mosquito-bitten skin of NSG mice were infected in vivo with 250 PFU SFV6 and then 
treated with topical IMQ at 1 hpi (with one re-application at 6hpi). Mice were left for 24 hours 
and  SFV RNA were quantified by qPCR in skin and spleen at 24 hpi, and infectious virus in the 970 
serum by plaque assay (n=6).  
(H-J) 6mm skin explants from WT and ccr2-null mice were infected with 1x105 PFU SFV6 and 
treated with a single 2 mg application of topical IMQ ex vivo. At 24 hpi, copy number of (H) 
SFV RNA, (I) ifnb1, and (J) host ISG (cxcl10, isg15, rsad2) were determined by qPCR (n=6).  
*p<0.05, **p<0.01, ns=not significant (Mann-Whitney and Kruskal-Wallis test). 975 
 
-
 
(A-C) Mosquito-bitten mouse skin was digested to release cells and then FACS-sorted at 4oC 
into ÒstromaÓ, ÒmacrophageÓ, dendritic cell ÒDCsÓ and Òother leukocyteÓ compartments as 980 
a bulk sort. All steps were undertaken in presence of transcriptional inhibitors. Copy number 
of gene transcripts were determined by qPCR for ifna4, ifnb1, isg15, cxcl10, rsad2 and 18S 
RNA (n=4). Cells were sourced from mosquito-bitten skin that was either; (A) infected with 250 
PFU SFV6 alone; (B) treated with topical IMQ alone (at 1h and reapplied at 6h); (C) infected 
with 250 PFU SFV6 and treated with topical IMQ at 1hpi (with one re-application at 6hpi). 985 
*p<0.05, ns=not significant (Mann-Whitney). 
 
 
  
(A) Primary mouse keratinocytes were infected with SFV4(Xho)-EGFP at an MOI of 0.1. At 6 hpi 990 
replication complexes (green) were present throughout cytoplasm (DAPI, blue).  
(B,C) Primary mouse embryonic fibroblasts were infected with SFV6 in vitro at an MOI of 0.1. 
At 1hpi, cells were treated with either 0.5, 2 or 10 μg/ml IMQ and at 24 hpi; (B) copy number 
of SFV RNA determined by qPCR (n=6) and infectious virus in the media were quantified by 
plaque assay; and (C) copy number of host cxcl10 gene transcripts was determined by qPCR 995 
(n=6). 
(D) Primary mouse dermal fibroblasts and BM-derived Flt3L DCs, GM-CSF DCs, and M-CSF 
macrophages were treated with 0.5 μg/ml IMQ for 24 hours. The resulting conditioned media 
was aspirated and placed on SFV6-Gluc-infected fibroblasts (1 hpi with at an MOI of 0.01). 
Virus-encoded Gluc was assayed at 24 hpi (n=6). 1000 
(E-G) Primary keratinocytes were infected in vitro with SFV6 (E,G) or SFV4(Xho)-eGFP (F)  at an 
MOI of 0.1, then at 1 hpi treated with 0.5 µg/ml IMQ in the presence or absence of Flt3-L DCÕs 
separated by a 0.5 μm transwell membrane. (E) Copy number of SFV RNA and host 18S RNA 
in the keratinocytes were determined by qPCR at 24 hpi (n=5-6). (F) SFV-encoded eGFP shown 
as green, with cell nuclei counter-stained with DAPI (blue). (G) Copy number of SFV RNA and 1005 
cxcl10 transcripts were determined in DC by qPCR at 24hpi (n=5-6).  
(H,I) Primary fibroblasts (H) or keratinocytes (I) were infected in vitro with SFV6 at an MOI of 
0.1 in the presence or absence of Flt3L-derived DCs separated from stromal cells by a 
transwell membrane. At 1 hpi cells were either left untreated or given 0.5 µg/ml IMQ. (H) Copy 
number of SFV RNA were determined by qPCR at 24hpi (n=5-6). (I) Gene expression of SFV-1010 
infected keratinocyte ISG were determined by qPCR (n=4) and significance determined by 2-
way ANOVA (*<p0.05, ****p<0.0001).  
*p<0.05, **p<0.01, ****p<0.0001, ns=not significant (Mann-Whitney and Kruskal-Wallis test). 
 
 1015 
. 
(A-C) Mosquito-bitten skin of mice (n=7-8) were infected with 25 000 PFU BUNV and treated 
with topical IMQ at 1 hpi (with one re-application at 6hpi). Copy number of BUNV RNA was 
determined by qPCR in skin (A) and dLN (B); and infectious virus in blood determined by 
plaque assay up to 72hpi (C).  1020 
(D-G) Mice were co-inoculated with 106 PFU of CHIKV (s.c.) and mosquito saliva (derived from 
5 Ae.aegypti mosquitoes) and treated with topical IMQ at 1hpi (with one re-application at 
6hpi). Dissemination of virus to distal joints were assessed at 5 days post infection in the right 
ankle joint (D,E) and both wrist joints (F,G). CHIKV RNA were quantified by qPCR and 
infectious virus titers quantified by TCID50 (n=10). 1025 
(H,I) Bisected human skin biopsies from 16 different donors were cultured as explants and 
infected with virus (1×105 PFU CHIKV (H) or 0.5x105 ZIKV (I)). One half of each biopsy was 
treated with a single application (2 mg) of topical IMQ ex vivo 1hpi; while the other half was 
left untreated. CHIKV and ZIKV RNA was quantified by qPCR at 24 and 48 hpi and virus titers 
in the media quantified by plaque assay. 1030 
*p<0.05, **p<0.01, ****p<0.0001, ns=not significant (Mann-Whitney). 
 
